BioPorto A/S (CPH:BIOPOR)

Market Cap	695.63M
Revenue (ttm)	34.45M
Net Income (ttm)	-82.15M
Shares Out	454.66M
EPS (ttm)	-0.19
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	163,273
Average Volume	272,698
Open	1.576
Previous Close	1.530
Day's Range	1.536 - 1.600
52-Week Range	1.200 - 2.850
Beta	0.93
RSI	55.21
Earnings Date	May 8, 2025

About BioPorto

BioPorto A/S, an in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the onset of disease states for management and therapies in Europe, North America, Asia, and internationally. It offers ProNephro AKI (NGAL), a test for pediatric acute kidney injury (AKI); NGAL Test, a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine, EDTA plasma, or heparin plasma on automated clinical chemistry analyzers to diagnose acu...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1917
• Employees: 48
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: BIOPOR

Financial Performance

In 2024, BioPorto's revenue was 36.24 million, an increase of 17.07% compared to the previous year's 30.96 million. Losses were -68.24 million, 21.2% more than in 2023.